KR910016336A - 용액 제제 - Google Patents

용액 제제 Download PDF

Info

Publication number
KR910016336A
KR910016336A KR1019910003135A KR910003135A KR910016336A KR 910016336 A KR910016336 A KR 910016336A KR 1019910003135 A KR1019910003135 A KR 1019910003135A KR 910003135 A KR910003135 A KR 910003135A KR 910016336 A KR910016336 A KR 910016336A
Authority
KR
South Korea
Prior art keywords
alkyl
represent
pharmaceutically acceptable
independently represent
och
Prior art date
Application number
KR1019910003135A
Other languages
English (en)
Other versions
KR0177158B1 (ko
Inventor
시게오 나까니시
이와오 야마나까
Original Assignee
후지사와 도모기찌로
후지사와 야꾸힝 고교 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 후지사와 도모기찌로, 후지사와 야꾸힝 고교 가부시끼가이샤 filed Critical 후지사와 도모기찌로
Publication of KR910016336A publication Critical patent/KR910016336A/ko
Application granted granted Critical
Publication of KR0177158B1 publication Critical patent/KR0177158B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)

Abstract

내용 없음

Description

용액 제제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (6)

  1. 하기 일반식(Ⅰ)의 화합물 또는 이의 약학적으로 허용되는 염. 약학적으로 허용되는 계면 활성제 및 약학적으로 허용되는 비수용매를 함유하는 용액제제.
    상기식에서, 치환기[R1및 R2],[R3및 R4]및 [R5및 R6]의 각각의 근접 쌍은 독립적으로 a) 두개의 근접 수소원자를 나타내거나 b) 이들이 부착되어 있는 근접 탄소원자간에 제2결합을 형성하고; 상기 의미외에, R2는 알킬 그룹을 나타낼 수 있으며; R7은 H, OH, 보호된 하이드록시 또는 O-알킬을 나타내거나 R1과 함께 =O를 나타낼 수 있으며; R8및 R9는 독립적으로 H 또는 OH를 나타내고; R10은 H, 알킬, 하나이상의 하이드록실 그룹으로 치환된 알킬, 알케닐, 하나이상의 히이드록실 그룹으로 치환된 알케닐 또는 =O로 치환된 알킬이고; X는 0, (H, 0H),(H,H)또는 -CH2O-이고; Y는 O, (H, OH)(H, H) 또는 N-NR11R12또는 N-OR13을 나타내고; R11및 R12는 독립적으로 H, 알킬, 아릴 또는 토실을 나타내고; R13,R14,R15,R16,R17,R18,R19,R22,및 R23은 독립적으로 H 또는 알킬이고; R20및 R21은 독립적으로 0을 나타내거나 (R20a, H) 및 (R21a, H)를 각각 나타낼 수 있으며; R20a및 R21a는 독립적으로 OH, O- 알킬 또는 OCH2OCH2COH2OCH3를 나타내거나 R21a는보호된 하이드록시이고 ; 또한 R20a 및 R21a는 함께 에폭시드 고리내의 산소원자를 나타낼 수 있으며; n은 1,2 또는 3이고; 상기 의미외에, Y,R10및R23은 이들이 부착되어 있는 탄소원자와 함께 5원 또는 6원 N-, S- 또는 O-함유 복소환식 고리를 나타낼 수 있으며, 이들은 포화 또는 불포화될 수 있고, 알킬, 하이드록시, 하나이상의 하이드록실 그룹으로 치환된 알킬, O-알킬, 벤질 및 -CH2Se(C6H5)중에서 선택된 하나이상의 그룹으로 치환될 수 있다.
  2. 제 1 항에 있어서, 화합물(Ⅰ) 또는 이의 약학적으로 허용되는 염과 약학적으로 허용되는 계면 활성제가 1:1 내지 1:100 중량비 범위인 용액 제제.
  3. 제2항에 있어서, 약학적으로 허용되는 계면 활성제가 피마자유-계면 활성제인 용액 제제.
  4. 제3항에 있어서, 약학적으로 허용되는 비수용매가 에틸알코올인 용액제제.
  5. 제4항에 있어서, 화합물(Ⅰ)이 17-알릴-1, 14-디히드록시-12-[2-(4-하이드록시-3-메톡시시클로헥실)-1-메틸비닐]-23,25-디메톡시-13,19,21,27-테트라메틸-11,28-디옥사-4-아자트리시클로-[22.3.1.04.9]옥타코스-18-엔-2,3,10,16-테트라온인 용액 제제.
  6. 하기 일반식(Ⅰ)의 화합물 또는 이의 약학적으로 허용되는 염 및 약학적으로 허용되는 계면 활성제를 약학적으로 허용되는 비수용매중에 용해시킴을 특징으로 하여 용액 제제를 제조하는 방법;
    상기식에서, 치환기[R1및 R2],[R3및 R4]및[R5및 R6]의 각각의 근접 쌍은 독립적으로 a)두개의 근접 수소원자를 나타내거나 b)이들이 부착되어 있는 근접 탄소원자간에 제2결합을 형성하고; 상기 의미외에. R2는 알킬 그룹을 나타낼 수 있으며; R7은 H,OH, 보호된 하이드록시 또는 O-알킬을 나타내거나 R1과 함께 =O를 나타낼 수 있으며; R3및 R4는 독립적으로 H또는 OH를 나타내고; R10은 H, 알킬 하나이상의 하이드록실 그룹으로 치환된 알킬, 알케닐, 하나이상의 하이드록실 그룹으로 치환된 알케닐 또는 =O로 치환된 알킬이고; X는 O, (H,OH)(H,H) 또는 -CH2O-이고; Y는 O, (H,OH),(H,H)또는 N-NR11R12또는 N-OR13을 나타내고; R11및 R12는 독립적으로 H, 알킬, 아릴 또는 토실을 나타내고; R13,R14,R15,R16,R17,R18,R19,R22,및 R23은 독립적으로 H 또는 알킬이고; R20및 R21은 독립적으로 O를 나타내거나 (R20a,H)및(R21a,H)를 각각 나타낼 수 있으며; R20a및 R21a는 독립적으로 OH, O-알킬 또는 OCH2OCH2OCH2OH3를 나타내거나 R21a는 보호된 하이드록시이고; 또한 R20a및 R21a는 함께 에폭시드 고리내의 산소 원자를 나타낼 수 있으며; n은 1,2 또는 3이고; 상기 의미외에, Y,R10및R23은 이들이 부착되어 있는 탄소원자와 함께 5원 또는 6원 N-, S- 또는 O-함유 복소환식 고리를 나타낼 수 있으며, 이들은 포화 또는 불포화될 수 있고, 알킬, 하이드록시, 하나이상의 하이드록실 그룹으로 치환된 알킬 O-알킬, 벤질 및-CH2Se(C6H5)중에서 선택된 하나이상의 그룹으로 치환될 수 있다.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019910003135A 1990-03-01 1991-02-27 면역억제 활성을 갖는 트리사이클릭 화합물 함유 용액 제제 KR0177158B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2-51110 1990-03-01
JP5111090 1990-03-01

Publications (2)

Publication Number Publication Date
KR910016336A true KR910016336A (ko) 1991-11-05
KR0177158B1 KR0177158B1 (ko) 1999-03-20

Family

ID=12877668

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910003135A KR0177158B1 (ko) 1990-03-01 1991-02-27 면역억제 활성을 갖는 트리사이클릭 화합물 함유 용액 제제

Country Status (20)

Country Link
EP (1) EP0444659B1 (ko)
JP (1) JP2522121B2 (ko)
KR (1) KR0177158B1 (ko)
CN (1) CN1028961C (ko)
AT (1) ATE143598T1 (ko)
AU (1) AU642707B2 (ko)
CA (1) CA2037408C (ko)
DE (1) DE69122418T2 (ko)
DK (1) DK0444659T3 (ko)
ES (1) ES2093650T3 (ko)
GR (1) GR3021777T3 (ko)
HK (1) HK62797A (ko)
HU (2) HU209436B (ko)
IE (1) IE75221B1 (ko)
MX (1) MX9203032A (ko)
PT (1) PT96916B (ko)
RU (1) RU2028142C1 (ko)
SG (1) SG47986A1 (ko)
UA (1) UA51608C2 (ko)
ZA (1) ZA911502B (ko)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143918A (en) * 1990-10-11 1992-09-01 Merck & Co., Inc. Halomacrolides and derivatives having immunosuppressive activity
IE65341B1 (en) * 1990-11-08 1995-10-18 Fujisawa Pharmaceutical Co Suspensions containing tricyclic compounds
US5147877A (en) * 1991-04-18 1992-09-15 Merck & Co. Inc. Semi-synthetic immunosuppressive macrolides
US5162334A (en) * 1991-05-13 1992-11-10 Merck & Co., Inc. Amino O-alkyl, O-alkenyl and O-alkynlmacrolides having immunosuppressive activity
US5565560A (en) * 1991-05-13 1996-10-15 Merck & Co., Inc. O-Aryl,O-alkyl,O-alkenyl and O-alkynylmacrolides having immunosuppressive activity
US5189042A (en) * 1991-08-22 1993-02-23 Merck & Co. Inc. Fluoromacrolides having immunosuppressive activity
US5208241A (en) * 1991-09-09 1993-05-04 Merck & Co., Inc. N-heteroaryl, n-alkylheteroaryl, n-alkenylheteroaryl and n-alkynylheteroarylmacrolides having immunosuppressive activity
ES2148224T3 (es) * 1992-03-30 2000-10-16 American Home Prod Formulacion de rapamicina para inyecciones intravenosas.
CH686761A5 (de) * 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
AT408520B (de) * 1993-05-27 2001-12-27 Novartis Erfind Verwalt Gmbh Galenische formulierungen
US5616588A (en) * 1993-09-30 1997-04-01 American Home Products Corporation Rapamycin formulation for IV injection
US5536729A (en) * 1993-09-30 1996-07-16 American Home Products Corporation Rapamycin formulations for oral administration
US5516770A (en) * 1993-09-30 1996-05-14 American Home Products Corporation Rapamycin formulation for IV injection
IL111004A (en) * 1993-09-30 1998-06-15 American Home Prod Oral formulations of rapamycin
US5693648A (en) * 1994-09-30 1997-12-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynyl-macrolides having immunosuppressive activity
TW426516B (en) * 1996-12-06 2001-03-21 Fujisawa Pharmaceutical Co An oral pharmaceutical composition in solid dispersion containing water-insoluble tricyclic compounds
PL1663216T3 (pl) 2003-08-29 2012-03-30 Veloxis Pharmaceuticals As Kompozycje o zmodyfikowanym uwalnianiu zawierające takrolimus
CN1859909B (zh) 2003-08-29 2011-04-06 生命周期药物公司 含有他克莫司的固态分散体
CN1765365B (zh) * 2004-09-29 2012-01-25 天马药业(集团)股份有限公司 提高苷或苷元类药物在胃内吸收的口服软胶囊
KR100866728B1 (ko) * 2004-11-12 2008-11-03 주식회사종근당 타크로리무스를 함유하는 주사제
FR2879932B1 (fr) * 2004-12-27 2007-03-23 Aventis Pharma Sa Formulations injectable ou administrable par voie orale de derives d'azetidine
DK2167033T3 (en) 2007-05-30 2017-08-14 Veloxis Pharmaceuticals As Once daily oral dosage form comprising tacrolism
CL2008000374A1 (es) 2008-02-05 2008-04-04 Igloo Zone Chile S A Composicion farmaceutica que comprende un polvo para suspension oral de tacrolimus o una de sus sales, hidratos o solvatos y excipientes farmaceuticamente aceptables; procedimiento de preparacion de dicha composicion farmaceutica; y uso para la preve
CN101869547B (zh) * 2009-04-24 2012-02-22 张娜 一种他克莫司注射制剂
WO2011100975A2 (en) 2010-02-17 2011-08-25 Lifecycle Pharma A/S Stabilized tacrolimus composition
CN117177749A (zh) 2021-03-03 2023-12-05 萨那生物科技公司 与心肌细胞疗法一起使用的免疫抑制疗法以及相关的方法和组合物
CN115463097B (zh) * 2021-06-11 2024-04-19 杭州中美华东制药有限公司 一种他克莫司缓释中间体颗粒的制备工艺

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8430455D0 (en) * 1984-12-03 1985-01-09 Fujisawa Pharmaceutical Co Fr-900506 substance
GB8608080D0 (en) * 1986-04-02 1986-05-08 Fujisawa Pharmaceutical Co Solid dispersion composition
CH677448A5 (ko) * 1987-11-09 1991-05-31 Sandoz Ag
EP0350164A3 (en) * 1988-06-13 1991-07-24 Beecham Group Plc Amphotericin derivatives

Also Published As

Publication number Publication date
EP0444659A3 (en) 1991-12-18
KR0177158B1 (ko) 1999-03-20
UA51608C2 (uk) 2002-12-16
SG47986A1 (en) 1998-04-17
AU642707B2 (en) 1993-10-28
IE75221B1 (en) 1997-08-27
GR3021777T3 (en) 1997-02-28
HU209436B (en) 1994-06-28
PT96916A (pt) 1991-11-29
ES2093650T3 (es) 1997-01-01
JP2522121B2 (ja) 1996-08-07
DK0444659T3 (da) 1996-11-18
HK62797A (en) 1997-05-16
HU211502A9 (en) 1995-11-28
CA2037408C (en) 2002-12-17
IE910679A1 (en) 1991-09-11
CN1055110A (zh) 1991-10-09
CA2037408A1 (en) 1991-09-02
HUT57043A (en) 1991-11-28
MX9203032A (es) 1992-07-31
HU910681D0 (en) 1991-09-30
PT96916B (pt) 1998-07-31
JPH04211012A (ja) 1992-08-03
ZA911502B (en) 1991-12-24
RU2028142C1 (ru) 1995-02-09
DE69122418T2 (de) 1997-03-06
CN1028961C (zh) 1995-06-21
AU7194991A (en) 1991-10-31
ATE143598T1 (de) 1996-10-15
DE69122418D1 (de) 1996-11-07
EP0444659A2 (en) 1991-09-04
EP0444659B1 (en) 1996-10-02

Similar Documents

Publication Publication Date Title
KR910016336A (ko) 용액 제제
KR910002454A (ko) 외부용 수성 액체 조성물
KR920005987A (ko) 트리사이클릭 화합물을 함유하는 연고제
KR920009401A (ko) 현탁 조성물 및 그의 제조방법
RU99114776A (ru) Лекарственные композиции
RU2000129665A (ru) Фармацевтическая композиция
ES2134860T3 (es) Preparacion farmaceutica de accion prolongada.
KR920009400A (ko) 약제학적 조성물
EP0428169B1 (en) Aqueous liquid formulations
US20080207670A1 (en) Dermally Applicable Formulations For Treating Skin Diseases in Animals
WO1991019495A1 (en) Use of a macrolide compound such as fk 506 for manufacturing a medicament for treating idiopathic thrombocytopenic purpura and basedow's disease
KR920700638A (ko) 가역적 폐색성 기도 질환 치료용 매크롤라이드
KR910004647A (ko) 마크로사이클 화합물
KR960700055A (ko) 뇌 허혈을 치료하기 위한 마크로라이드의 용도(Use of macrolides for the treatment of cerebral ischemia)
KR860004045A (ko) 폴리사이클릭화합물의 제조방법 및 그 약학적 제제
US5643901A (en) Medicament for treating idiopathic thrombocytopenic purpura
GB2246350A (en) Tricyclo compounds
RU2003137599A (ru) Фармацевтическая композиция
JPH04182429A (ja) 非水溶液製剤
RU2001127531A (ru) Липосомные препараты
KR890001528A (ko) 성인 t-세포 백혈병/임파종의 억제를 위한 아바론, 아바롤 및 그 유도체의 용도
KR920009829A (ko) 광학 활성 1,6-나프티리딘 유도체

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20101116

Year of fee payment: 13

EXPY Expiration of term